First City Capital Management’s GSK GSK Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q3
Sell
-5,234
Closed -$201K 153
2025
Q2
$201K Buy
5,234
+10
+0.2% +$382 0.12% 144
2025
Q1
$202K Buy
+5,224
New +$191K 0.12% 144
2024
Q4
Sell
-7,488
Closed -$306K 161
2024
Q3
$306K Sell
7,488
-1,220
-14% -$49.9K 0.16% 130
2024
Q2
$335K Sell
8,708
-1,991
-19% -$83.8K 0.19% 121
2024
Q1
$459K Sell
10,699
-160
-1% -$6.6K 0.25% 99
2023
Q4
$402K Sell
10,859
-6,475
-37% -$232K 0.23% 107
2023
Q3
$628K Sell
17,334
-2,883
-14% -$102K 0.39% 71
2023
Q2
$721K Sell
20,217
-4,460
-18% -$160K 0.43% 65
2023
Q1
$889K Buy
24,677
+880
+4% +$30.8K 0.52% 52
2022
Q4
$836K Sell
23,797
-1,756
-7% -$58.5K 0.5% 54
2022
Q3
$752K Buy
25,553
+2,318
+10% +$87.9K 0.5% 57
2022
Q2
$1.26M Buy
23,235
+800
+4% +$44.2K 0.78% 42
2022
Q1
$1.22M Buy
22,435
+360
+2% +$19.6K 0.67% 45
2021
Q4
$1.24M Sell
22,075
-920
-4% -$47.9K 0.7% 44
2021
Q3
$1.1M Sell
22,995
-431
-2% -$21.6K 0.62% 49
2021
Q2
$1.21M Buy
23,426
+373
+2% +$17.9K 0.66% 48
2021
Q1
$1.1M Buy
23,053
+1,894
+9% +$86K 0.64% 50
2020
Q4
$934K Sell
21,159
-26,856
-56% -$1.23M 0.6% 50
2020
Q3
$2.23M Buy
48,015
+22,765
+90% +$1.14M 0.83% 40
2020
Q2
$1.29M Sell
25,250
-700
-3% -$35.9K 0.99% 35
2020
Q1
$1.23M Sell
25,950
-632
-2% -$33.7K 1.2% 31
2019
Q4
$1.56M Buy
26,582
+127
+0.5% +$7.06K 1.07% 34
2019
Q3
$1.41M Sell
26,455
-161
-0.6% -$8.28K 1.03% 36
2019
Q2
$1.33M Sell
26,616
-566
-2% -$28.4K 0.97% 38
2019
Q1
$1.42M Sell
27,182
-1,680
-6% -$83.9K 1.02% 33
2018
Q4
$1.38M Buy
28,862
+46
+0.2% +$2.27K 1.08% 30
2018
Q3
$1.45M Buy
28,816
+320
+1% +$16.3K 0.96% 38
2018
Q2
$1.44M Sell
28,496
-40
-0.1% -$2.02K 1.03% 36
2018
Q1
$1.39M Hold
28,536
1.04% 37
2017
Q4
$1.26M Sell
28,536
-288
-1% -$13.3K 0.86% 44
2017
Q3
$1.46M Buy
28,824
+60
+0.2% +$3.04K 1.02% 32
2017
Q2
$1.55M Buy
28,764
+40
+0.1% +$2.13K 1.12% 30
2017
Q1
$1.51M Sell
28,724
-2,480
-8% -$126K 1.12% 30
2016
Q4
$1.5M Buy
31,204
+1,567
+5% +$77.4K 1.13% 29
2016
Q3
$1.6M Buy
29,637
+320
+1% +$17.5K 1.22% 23
2016
Q2
$1.59M Buy
29,317
+940
+3% +$49.5K 1.2% 24
2016
Q1
$1.44M Sell
28,377
-82
-0.3% -$4.08K 0.98% 25
2015
Q4
$1.44M Buy
28,459
+2,625
+10% +$134K 0.96% 26
2015
Q3
$1.24M Buy
25,834
+1,697
+7% +$88.3K 0.91% 29
2015
Q2
$1.26M Sell
24,137
-560
-2% -$31.5K 0.87% 32
2015
Q1
$1.42M Buy
24,697
+1,100
+5% +$63.1K 0.99% 25
2014
Q4
$1.26M Sell
23,597
-60
-0.3% -$3.36K 0.87% 29
2014
Q3
$1.36M Sell
23,657
-161
-0.7% -$9.87K 0.97% 26
2014
Q2
$1.59M Buy
23,818
+6
+0% +$406 1.13% 18
2014
Q1
$1.59M Sell
23,812
-400
-2% -$27K 1.14% 18
2013
Q4
$1.62M Sell
24,212
-906
-4% -$58.7K 1.32% 17
2013
Q3
$1.58M Buy
25,118
+401
+2% +$25.8K 1.3% 17
2013
Q2
$1.54M Buy
+24,717
New +$1.57M 1.41% 18

Other funds holding GSK

First City Capital Management's GSK Position: Q3 2025 in Review

First City Capital Management sold out of GSK (GSK) in Q3 2025, closing a stake of 5,234 shares — an estimated $201K sold.

First City Capital Management first reported a position in GSK in Q2 2013 and held it in 48 quarters. The position peaked at $2.23M in Q3 2020. 895 funds tracked by Wall St. Rank hold GSK as of Q3 2025.

  • First City Capital Management reported no remaining GSK position as of Q3 2025 after selling out during the quarter.
  • First City Capital Management sold 5,234 GSK shares in Q3 2025, an estimated $201K.
  • First City Capital Management first reported a position in GSK in Q2 2013 and held it in 48 quarters.
  • First City Capital Management's GSK position peaked at $2.23M in Q3 2020.
  • 895 funds tracked by Wall St. Rank held GSK as of Q3 2025.

Based on First City Capital Management's 13F filing for Q3 2025, filed 21 Oct 2025.